reports
Merrimack Pharmaceuticals Inc: 1 director
A director at Merrimack Pharmaceuticals Inc bought 49,550 shares at 13.154USD and the significance rating of the trade was 67/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last t...
MERRIMACK PHARMS.INCO. suffers a double requalification, which weighs ...
The independent financial analyst theScreener just downgraded the general evaluation of MERRIMACK PHARMS.INCO. (US), active in the Biotechnology industry. As regards its fundamental valuation, the title loses a star(s) and now shows 1 out of 4 stars. Its market behaviour is also negatively reassessed and may be considered as moderately risky. theScreener believes that this double requalification keeps the title under pressure and justifies an overall rating downgrade to Slightly Negative. As of ...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.